The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -1.47 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M 7.90 — flag raised, worth a closer lookWatch
- Earnings quality 83/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as X4 Pharmaceuticals, Inc reports it. History and quarterly detail are in the app.
- License and other revenue$28.6M
- Product revenue, net$6.5M
Leadership changes
From X4 Pharmaceuticals, Inc's own filings, the day they're filed.
- Kelly Gold · director · appointmenteff. 2026-07-01
- John Volpone · Chief Operating Officer · appointmenteff. 2025-09-16
- Christophe Arbet-Engels · Chief Medical Officer · departureeff. 2025-09-15
Latest filings
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-07-01
- 8-K · Company announcement2026-05-12
- 10-Q · Quarterly report2026-05-06
- DEF 14A · Annual proxy (pay & governance)2026-03-20
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about X4 Pharmaceuticals, Inc, every answer cited to the official filings🔒
- The Intelligence Brief — added when X4 Pharmaceuticals, Inc's brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.